FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2611116831> ?p ?o ?g. }

• W2611116831 endingPage "4571" @default.
• W2611116831 startingPage "4571" @default.
• W2611116831 abstract "Abstract Background: Concerns have been raised whether immune checkpoint inhibitor therapy in the alloBMT setting will result in graft versus host disease (GvHD) and transplant related mortality (TRM). We report our experience with a variety of checkpoint inhibitors used before or after allogeneic bone marrow transplantation (alloBMT). Our series comprises patients who received T cell-replete hematopoietic stem cells from HLA-haploidentical or -matched donors and is limited to those treated with post-transplant cyclophosphamide (PTCy) as primary GvHD prophylaxis. Patient selection: We retrospectively reviewed the records of alloBMT recipients who received PTCy and received checkpoint inhibitor therapy before or after alloBMT. GvHD was assessed using the CIBMTR GVHD index. Results: Eleven patients received checkpoint inhibitor therapy prior to alloBMT: anti-PD-1: Nivolumab n=6, anti-CTLA4: Ipilimumab n=8 (3 patients received both nivolumab and ipilimumab). These patients received a median of 4 (range 1 - 18) cycles of therapy. The median interval from last checkpoint inhibitor treatment to day of transplant was 43 (range 18-302) days. All patients received nonmyeloablative conditioning; 6 received partially mismatched allografts (5 were HLA haploidentical). Four patients developed Grade II aGvHD: Three patients who had received partially mismatched allografts (haplo-2, 9/10 unrelated-1) experienced stage 3 cutaneous GvHD only; one patient who received a 10/10 unrelated donor allograft developed stage 3 cutaneous GvHD with stage 1 liver involvement. Three patients were on immunosuppression when GvHD developed, the fourth patient with cutaneous and liver GvHD had been taken off tacrolimus on day 68 due to concerns of graft failure. GvHD resolved with treatment in each case. None of these patients developed chronic GvHD and none have died [median follow-up of 0.66 (range 0.91 - 2.0) years post alloBMT]. Nine patients received checkpoint therapy following alloBMT: anti-PD-1: Pembrolizumab n = 1, Nivolumab n= 6, anti-CTLA4: Ipilimumab n= 3 (one patient received nivolumab and ipilimumab). Eight patients had received nonmyeloablative conditioning; 5 received haploidentical allografts. Six received treatment for relapse of their hematologic malignancy, 1 for relapsed pediatric sarcoma, and 2 for newly diagnosed lung cancer. The median time to initiation of checkpoint inhibitor therapy was 1.2 (range: 0.8 - 5.8) years post alloBMT. Patients received a median of 5 (range 1 - 24) cycles of therapy. There was 1 case of Grade II aGvHD; stage 3 cutaneous GvHD when DLI from a 10/10 matched unrelated donor was given for relapsed disease after ipilimumab. This resulted in GvHD which was not accompanied by the desired graft-vs-leukemia effect. There were no other cases of acute or chronic GvHD in this group. There were 4 tumor-related deaths: pediatric sarcoma (1), lung cancer (1), and AML (2). The median follow-up for this group is 2 years (range 0.85 - 8.0) post alloBMT. Conclusions: In this small series, the incidence and severity of GvHD seen in patients who received checkpoint inhibitors was similar to that seen in patients treated with PTCy as GvHD prophylaxis without checkpoint inhibitors. GvHD was seen in patients treated with checkpoint inhibitors prior to alloBMT, but was generally mild and readily controlled and there were no associated deaths. In patients treated with checkpoint inhibitors after alloBMT, the only case of GvHD occurred after the patient received DLI. We caution that use of checkpoint inhibitors in closer temporal proximity to transplant might well be associated with increased risk of GvHD or severity of GvHD. Disclosures Borrello: WindMIL Therapeutics: Equity Ownership, Patents & Royalties, Research Funding; Celgene: Honoraria, Research Funding, Speakers Bureau; BMS: Honoraria, Research Funding. Wagner-Johnston:Seattle Genetics: Research Funding. Smith:Celgene: Consultancy, Other: member of DSMB." @default.
• W2611116831 created "2017-05-12" @default.
• W2611116831 creator A5002822530 @default.
• W2611116831 creator A5003078712 @default.
• W2611116831 creator A5005953560 @default.
• W2611116831 creator A5012395020 @default.
• W2611116831 creator A5034420962 @default.
• W2611116831 creator A5034547254 @default.
• W2611116831 creator A5035050411 @default.
• W2611116831 creator A5035609080 @default.
• W2611116831 creator A5036664711 @default.
• W2611116831 creator A5036866696 @default.
• W2611116831 creator A5044224857 @default.
• W2611116831 creator A5046719320 @default.
• W2611116831 creator A5065373363 @default.
• W2611116831 creator A5068492086 @default.
• W2611116831 creator A5068593672 @default.
• W2611116831 creator A5069675791 @default.
• W2611116831 creator A5091275921 @default.
• W2611116831 date "2016-12-02" @default.
• W2611116831 modified "2023-10-01" @default.
• W2611116831 title "Checkpoint Inhibitor Therapy and Graft Versus Host Disease in Allogeneic Bone Marrow Transplant Recipients of Haploidentical and Matched Products with Post-Transplant Cyclophosphamide." @default.
• W2611116831 doi "https://doi.org/10.1182/blood.v128.22.4571.4571" @default.
• W2611116831 hasPublicationYear "2016" @default.
• W2611116831 type Work @default.
• W2611116831 sameAs 2611116831 @default.
• W2611116831 citedByCount "16" @default.
• W2611116831 countsByYear W26111168312017 @default.
• W2611116831 countsByYear W26111168312018 @default.
• W2611116831 countsByYear W26111168312019 @default.
• W2611116831 countsByYear W26111168312021 @default.
• W2611116831 countsByYear W26111168312022 @default.
• W2611116831 crossrefType "journal-article" @default.
• W2611116831 hasAuthorship W2611116831A5002822530 @default.
• W2611116831 hasAuthorship W2611116831A5003078712 @default.
• W2611116831 hasAuthorship W2611116831A5005953560 @default.
• W2611116831 hasAuthorship W2611116831A5012395020 @default.
• W2611116831 hasAuthorship W2611116831A5034420962 @default.
• W2611116831 hasAuthorship W2611116831A5034547254 @default.
• W2611116831 hasAuthorship W2611116831A5035050411 @default.
• W2611116831 hasAuthorship W2611116831A5035609080 @default.
• W2611116831 hasAuthorship W2611116831A5036664711 @default.
• W2611116831 hasAuthorship W2611116831A5036866696 @default.
• W2611116831 hasAuthorship W2611116831A5044224857 @default.
• W2611116831 hasAuthorship W2611116831A5046719320 @default.
• W2611116831 hasAuthorship W2611116831A5065373363 @default.
• W2611116831 hasAuthorship W2611116831A5068492086 @default.
• W2611116831 hasAuthorship W2611116831A5068593672 @default.
• W2611116831 hasAuthorship W2611116831A5069675791 @default.
• W2611116831 hasAuthorship W2611116831A5091275921 @default.
• W2611116831 hasConcept C121608353 @default.
• W2611116831 hasConcept C126322002 @default.
• W2611116831 hasConcept C141071460 @default.
• W2611116831 hasConcept C143998085 @default.
• W2611116831 hasConcept C2776694085 @default.
• W2611116831 hasConcept C2776755627 @default.
• W2611116831 hasConcept C2777701055 @default.
• W2611116831 hasConcept C2779972918 @default.
• W2611116831 hasConcept C2780030458 @default.
• W2611116831 hasConcept C2780252810 @default.
• W2611116831 hasConcept C2781433595 @default.
• W2611116831 hasConcept C2909675724 @default.
• W2611116831 hasConcept C2911091166 @default.
• W2611116831 hasConcept C71924100 @default.
• W2611116831 hasConcept C90924648 @default.
• W2611116831 hasConceptScore W2611116831C121608353 @default.
• W2611116831 hasConceptScore W2611116831C126322002 @default.
• W2611116831 hasConceptScore W2611116831C141071460 @default.
• W2611116831 hasConceptScore W2611116831C143998085 @default.
• W2611116831 hasConceptScore W2611116831C2776694085 @default.
• W2611116831 hasConceptScore W2611116831C2776755627 @default.
• W2611116831 hasConceptScore W2611116831C2777701055 @default.
• W2611116831 hasConceptScore W2611116831C2779972918 @default.
• W2611116831 hasConceptScore W2611116831C2780030458 @default.
• W2611116831 hasConceptScore W2611116831C2780252810 @default.
• W2611116831 hasConceptScore W2611116831C2781433595 @default.
• W2611116831 hasConceptScore W2611116831C2909675724 @default.
• W2611116831 hasConceptScore W2611116831C2911091166 @default.
• W2611116831 hasConceptScore W2611116831C71924100 @default.
• W2611116831 hasConceptScore W2611116831C90924648 @default.
• W2611116831 hasIssue "22" @default.
• W2611116831 hasLocation W26111168311 @default.
• W2611116831 hasOpenAccess W2611116831 @default.
• W2611116831 hasPrimaryLocation W26111168311 @default.
• W2611116831 hasRelatedWork W2075710004 @default.
• W2611116831 hasRelatedWork W2155654588 @default.
• W2611116831 hasRelatedWork W2234309584 @default.
• W2611116831 hasRelatedWork W2568130105 @default.
• W2611116831 hasRelatedWork W2611116831 @default.
• W2611116831 hasRelatedWork W2899970113 @default.
• W2611116831 hasRelatedWork W2947988614 @default.
• W2611116831 hasRelatedWork W2976744492 @default.
• W2611116831 hasRelatedWork W3120004960 @default.
• W2611116831 hasRelatedWork W4318473990 @default.
• W2611116831 hasVolume "128" @default.
• W2611116831 isParatext "false" @default.
• W2611116831 isRetracted "false" @default.
• W2611116831 magId "2611116831" @default.

• next